November 1, 2023
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
October 31, 2023
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
October 22, 2023
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
October 13, 2023
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
October 4, 2023
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
September 19, 2023
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
August 17, 2023
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 8, 2023
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 3, 2023
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 1, 2023
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital